Skip to main content
PMC home page
British Medical Journal logoLink to British Medical Journal
letter
. 1970 Nov 7;4(5731):344–346. doi: 10.1136/bmj.4.5731.344

Inhibition of Metastatic Spread by I.C.R.F. 159: Selective Deletion of a Malignant Characteristic

A J Salsbury, Karen Burrage, K Hellmann
PMCID: PMC1819662  PMID: 5528754

Abstract

Treatment with I.C.R.F. 159 completely inhibited metastasis formation in mice implanted with Lewis lung carcinoma at doses having little influence on the rate of growth of the primary implant. This inhibition was due to the effect of I.C.R.F. 159 on the development of blood vessels of the invading margins of the primary tumour. So far as is known, this is the first time a drug has induced a specific loss of the malignant characteristic of blood-borne tumour cell dissemination.

Full text

PDF
344

Images in this article

345Fig. 1
on p.345
345Fig. 2
on p.345
345Fig. 3
on p.345

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Burrage K., Hellmann K., Salsbury A. J. Drug-induced inhibition of tumour cell dissemination. Br J Pharmacol. 1970 May;39(1):205P–206P. [PMC free article] [PubMed] [Google Scholar]
  2. Creighton A. M., Hellmann K., Whitecross S. Antitumour activity in a series of bisdiketopiperazines. Nature. 1969 Apr 26;222(5191):384–385. doi: 10.1038/222384a0. [DOI] [PubMed] [Google Scholar]
  3. Donelli M. G., Rosso R., Garattini S. Quantitative studies on cancer dissemination. Cancer Res. 1969 Feb;29(2):414–418. [PubMed] [Google Scholar]
  4. HANDLER A. H., SARRIS T. G., WILLS C. CHEMOTHERAPY STUDIES ON PRIMARY TUMOR GRAFTS AND METASTASES IN HAMSTERS AND MICE. Acta Unio Int Contra Cancrum. 1964;20:176–179. [PubMed] [Google Scholar]
  5. Hellmann K., Burrage K. Control of malignant metastases by ICRF l59. Nature. 1969 Oct 18;224(5216):273–275. doi: 10.1038/224273a0. [DOI] [PubMed] [Google Scholar]
  6. Hellmann K., Field E. O. Effect of ICRF159 on the mammalian cell cycle: significance for its use in cancer chemotherapy. J Natl Cancer Inst. 1970 Mar;44(3):539–543. [PubMed] [Google Scholar]
  7. Hellmann K., Marshall P. G., Stayt S. The antitumour activity of a series of benzothiophenes. Biochem Pharmacol. 1967 Apr;16(4):681–687. doi: 10.1016/0006-2952(67)90081-0. [DOI] [PubMed] [Google Scholar]
  8. Hellmann K., Newton K. A., Whitmore D. N., Hanham I. W., Bond J. V. Preliminary clinical assessment of I.C.R.F. 159 in acute leukaemia and lymphosarcoma. Br Med J. 1969 Mar 29;1(5647):822–824. doi: 10.1136/bmj.1.5647.822. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Higgins G. A., White G. E. Cancer chemotherapy and surgery. Surg Clin North Am. 1968 Aug;48(4):839–850. doi: 10.1016/s0039-6109(16)38586-3. [DOI] [PubMed] [Google Scholar]
  10. Ketcham A. S., Wexler H., Minton J. P. Experimental study of metastases. JAMA. 1966 Oct 10;198(2):157–164. [PubMed] [Google Scholar]
  11. Rosso R., Donelli M. G., Franchi G., Garattini S. Effect of Triton WR 1339 on cancer dissemination and metastases. Eur J Cancer. 1969 Feb;5(1):77–78. doi: 10.1016/0014-2964(69)90092-9. [DOI] [PubMed] [Google Scholar]
  12. Sharpe H. B., Field E. O., Hellmann K. Mode of action of the cytostatic agent "ICRF 159". Nature. 1970 May 9;226(5245):524–526. doi: 10.1038/226524a0. [DOI] [PubMed] [Google Scholar]
  13. Wexler H., Ryan J. J., Ketcham A. S. The study of circulating tumor cells by the formation of pulmonary embolic tumor growths in a secondary host. Cancer. 1969 Apr;23(4):946–951. doi: 10.1002/1097-0142(196904)23:4<946::aid-cncr2820230433>3.0.co;2-u. [DOI] [PubMed] [Google Scholar]

Articles from British Medical Journal are provided here courtesy of BMJ Publishing Group

RESOURCES